Dunia Abdul-Aziz

Dunia Abdul-Aziz

Auto-generated profile, based on publicly available information

Dunia Abdul-Aziz

Department of Otolaryngology, Harvard Medical School, Boston, MA, USA; Eaton-Peabody Laboratory, Massachusetts Eye and Ear, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2023 in Cell Reports
Verified
Journal Article
Open access
GKGurmannat Kalra
Gurmannat Kalra
DLDanielle Lenz
Danielle Lenz
DADunia Abdul-Aziz
Dunia Abdul-Aziz
CHCraig Hanna
Craig Hanna
MBMahashweta Basu
Mahashweta Basu
AEAlbert S.B. Edge
Albert S.B. Edge
We explore the changes in chromatin accessibility and transcriptional programs for cochlear hair cell differentiation from postmitotic supporting cells using organoids from postnatal cochlea. The organoids contain cells with transcriptional signatures of differentiating vestibular and cochlear hair cells. Construction of trajectories identifies Lgr5+ cells as progenitors for hair cells, and the genomic data reveal gene regulatory networks leading to hair cells. We validate these networks, demonstrating dynamic changes both in expression and predicted binding sites of transcription factors (TFs) during organoid differentiation. We identify known regulators of hair cell development, Atoh1, Pou4f3, and Gfi1, and the analysis predicts the regulatory factors Tcf4, an E-protein and heterodimerization partner of Atoh1, and Ddit3, a CCAAT/enhancer-binding protein (C/EBP) that represses Hes1 and activates transcription of Wnt-signaling-related genes. Deciphering the signals for hair cell regeneration from mammalian cochlear supporting cells reveals candidates for hair cell (HC) regeneration, which is limited in the adult.

11 March 2005 in Biochemistry
Verified
Journal Article
Closed access
DADunia Abdul-Aziz
Dunia Abdul-Aziz
CFCarl Fisher
Carl Fisher
NBNatalia Beglova
Natalia Beglova
SBStephen C. Blacklow
Stephen C. Blacklow

14 May 2020 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
FSFelipe Santos
Felipe Santos
ESEdina Shu
Edina Shu
DLDaniel J. Lee
Daniel J. Lee
DJDavid H. Jung
David H. Jung
AQAlicia M. Quesnel
Alicia M. Quesnel
DWD. Bradley Welling
D. Bradley Welling
Objective: To determine the efficacy of fibroblast growth factor‐2 (FGF‐2) in treating chronic nonhealing tympanic membrane (TM) perforations.Method: Double‐blinded, randomized placebo controlled phase 2 clinical trial for patients with chronic TM perforations of more than 3 months duration with a cross‐over arm. Patients received either FGF‐2 or placebo (sterile water) saturated gelatin sponge in the perforation after rimming the perforation under topical anesthesia. The perforation was then covered with Tisseel fibrin glue. The primary endpoint was complete closure of the TM perforation. Secondary end points included change in hearing and partial TM closure rates. The TM was examined every 3 weeks with otoendoscopy for closure. The treatment was repeated if there was incomplete closure every 3 weeks up to a total of three treatments per arm.Results: Seventy four patients were recruited for the study. Fifty seven met eligibility criteria and fifty four completed the study. Ten of 14 perforations closed completely in the placebo group (71.4%) and 23 of 40 perforations closed completely in the FGF‐2 treatment group (57.5%), P value = .36. Pure tone averages and word recognition scores were not statistically significantly different between study groups post‐treatment. After initial complete closure, re‐perforation occurred in seven FGF‐2 treated patients and two placebo patients making the effective final closure rate 40% for FGF and 57% for placebo, respectively.Conclusion: No statistically significant difference in tympanic membrane perforation closure rate was found between the FGF‐2 and placebo groups. There were no differences in hearing outcomes between the groups.Level of evidence: 1b.